DSP-0337 / Sumitomo Pharma - LARVOL DELTA

A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile (clinicaltrials.gov) - P1; N=23; Terminated; Sponsor: Sumitomo Dainippon Pharma Oncology, Inc; N=90 ➔ 23; Recruiting ➔ Terminated; Alternate development strategy

Clinical • Enrollment change • Trial termination • Oncology • Solid Tumor